Syros Pharmaceuticals Inc (0S90.SG)
Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
At close: 08:31PM CEST
| Previous Close | 4.8600 |
| Open | 4.9600 |
| Bid | 5.0000 x N/A |
| Ask | 5.2000 x N/A |
| Day's Range | 4.8400 - 4.9600 |
| 52 Week Range | 1.9600 - 7.2600 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Simply Wall St.Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week
Key Insights Significantly high institutional ownership implies Syros Pharmaceuticals' stock price is sensitive to...
Business WireSyros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
CAMBRIDGE, Mass., June 13, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a webcast event with medical experts to discuss the unmet need in higher-risk myelodysplastic syndrome (HR-MDS) and the opportunity for tamibarotene to transform the care of newly diagnosed patients with RARA gene overexpression. The event will take place on Tuesday
- GuruFocus.com
Syros Pharmaceuticals Inc (SYRS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Explore key updates on clinical trials, financial shifts, and strategic insights from Syros Pharmaceuticals' Q1 2024 earnings call.
© 2024 Yahoo. All rights reserved.